Drug Trial Radar · NCT06625710
Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Oct 8, 2024
Primary completion
Aug 25, 2025
Study completion Aug 25, 2025
Sponsor
- Lead sponsor
- GemVax & KaelIndustry
- Sponsor type
- Industry
- First posted
- Oct 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the the safety, tolerability and pharmacokinetic characteristics after single and multiple administration of GV1001 in healthy subjects. The main questions it aims to answer are: Safety and Tolerability of GV1001 in different dose scheme, and PK Characteristics of GV1001 in differenct dose scheme Part A: single dose, 8 days clinical trial participation including one 3-day hospitalization Part B \& Extra Cohort: Multiple dose, 42 days clinical trial participation (12 days treatment + 30 days safety follow-up) including two times of 3-day hospitalization.
Conditions
- Neuro-Degenerative Disease
Interventions
GV1001Drug
Lyophilized peptide from hTERT
PlaceboDrug
0.9 % Normal Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of GV1001Time frame: 6 weeks
- PK Characteristics of GV1001Time frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.